Amvuttra 25 mg solution for injection in pre-filled syringe
Sponsors
Alnylam Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc.
Conditions
Hereditary Transthyretin AmyloidosisHereditary transthyretin-mediated amyloidosis with polyneuropathyTransthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Phase 3
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
CompletedCTIS2023-508365-33-00
Start: 2019-04-09End: 2025-07-17Target: 44Updated: 2025-02-25
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Active, not recruitingCTIS2024-518318-25-00
Start: 2020-06-24Target: 441Updated: 2025-07-25
An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
RecruitingCTIS2024-518343-38-00
Start: 2025-02-12Target: 208Updated: 2025-07-16
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
Not yet recruitingCTIS2025-522544-40-00
Target: 7Updated: 2026-02-20